Celgene (CELG) says a Revlimid/ dexamethasone combo met its primary PFS endpoint in a Phase III...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG) says a Revlimid/ dexamethasone combo met its primary PFS endpoint in a Phase III study of newly diagnosed multiple myeloma patients. Shares +2.5% premarket. (PR)